Stem Cell Therapies and Regenerative Medicine: Current Applications and Future Possibilities

Table of Contents

• INTRODUCTION
  • REASON FOR DOING THE STUDY
  • STUDY GOAL AND OBJECTIVES
  • CONTRIBUTIONS OF THE STUDY AND FOR WHOM
  • SCOPE AND FORMAT
  • METHODOLOGY AND INFORMATION SOURCES
  • ANALYSTS CREDENTIALS
  • OTHER RELEVANT BCC REPORTS AND PUBLICATIONS
  • BCC ONLINE SERVICES
  • DISCLAIMER
• SUMMARY
  • Summary Table: GLOBAL FORECAST OF REVENUES FOR STEM CELL AND CYTOKINE THERAPIES IN REGENERATIVE MEDICINE, THROUGH 2010 ($ BILLIONS)
  • Summary Figure: GLOBAL FORECAST OF REVENUES FOR STEM CELL AND CYTOKINE THERAPIES IN REGENERATIVE MEDICINE, 2003-2010 ($ BILLIONS)
• OVERVIEW
  • Table 1 PERCENT OF PERSONS USING PRESCRIPTION DRUGS IN THE PAST MONTH IN THE U.S., 1999-2000
    • GROWTH FACTORS AND CYTOKINES
  • Table 2 SELECTED CYTOKINES OR GROWTH FACTORS RELEVANT TO REGENERATIVE MEDICINE
  • Table 2 (CONTINUED)
    • STEM AND PROGENITOR CELLS
    • WORLDWIDE MARKETS FOR REGENERATIVE MEDICINE
  • Table 3 LEADING CAUSES OF DEATH IN THE U.S., 2001
  • Table 4 PREVALENCE OF MEDICAL CONDITIONS IN THE U.S. WITH POTENTIAL CELL THERAPIES
  • Table 5 AGING OF THE U.S. POPULATION
    • CELL THERAPIES AS A SUBSTITUTE FOR TRANSPLANTS
    • THE U.S. MARKET VERSUS THE REST OF THE WORLD
      • The U.S. Market versus the (Continued)
  • Table 6 POPULATION OF COUNTRIES OF THE EUROPEAN UNION, 2003
    • DISTRIBUTION OF REVENUES AND EFFORT
    • TYPES OF STEM OR PROGENITOR CELLS
  • Table 7 DESCENDANTS OF THE HUMAN MESENCHYMAL STEM CELL
    • Autologous Cells
    • Allogeneic Cells
    • UMBILICAL CORD BLOOD
  • Table 8 A PARTIAL LIST OF DISEASES TREATED USING CORD BLOOD STEM CELLS
    • EMBRYONIC STEM CELLS
      • Embryonic Stem Cells (Continued)
  • Table 9 DERIVATION OF BODY TISSUE TYPES FROM GERM LAYERS
  • Table 10 CELL TYPES DERIVED FROM EMBRYONIC STEM CELLS IN VITRO
  • Table 10 (CONTINUED)
    • Identification of Stem Cells
  • Table 11 MARKERS OF PLURIPOTENT CELLS IN MOUSE, MAN, AND MONKEY
    • Therapeutic Cloning
      • Therapeutic Cloning (Continued)
    • Utility of ES Cells
    • Ethical Considerations
      • Position of the Catholic Church
      • Position of the National Academy of Sciences
    • Politics and Funding for Embryonic Stem Cell Research
      • Politics and Funding for Embryonic Continued)
    • NIH Guidelines
      • NIH Guidelines (Continued)
  • Table 12 EMBRYONIC STEM CELL LINES THAT MEET NIH FUNDING REQUIREMENTS, WHICH ARE AVAILABLE FOR SHIPPING
    • Patents
    • GERM CELLS
    • WHAT MAKES A STEM CELL A STEM CELL?
    • CELL-BASED GENE THERAPY
    • U.S. REGULATION
      • DEVICES
  • Table 13 FOOD AND DRUG ADMINISTRATION BODIES INVOLVED IN IMPLANT REGULATION
    • BIOLOGICALS
      • Biologicals (Continued)
    • ORPHAN PRODUCT STATUS
    • INTERNATIONAL ISSUES
    • OFFSHORE CELL-THERAPY TREATMENTS
      • OFFSHORE CELL-THERAPY TREATMENTS (CONTINUED)
• APPLICATIONS FOR PROGENITOR CELL THERAPIES
  • APPLICATIONS OF REGENERATIVE MEDICINE FOR BLOOD AND THE IMMUNE SYSTEM
  • Figure 1 HEMATOPOIESIS
    • APPLICATIONS OF REGENERATIVE CONTINUED)
  • Table 14 A PARTIAL LIST OF DISEASES TREATED WITH HEMATOPOIETIC STEM CELLS
  • Table 14 (CONTINUED)
    • HARVESTING HEMATOPOIETIC STEM CELLS
      • Bone Marrow
      • Peripheral Blood Progenitor Cell Collection
      • Umbilical Cord Blood
      • Drug-Resistant Hematopoietic Stem Cells
    • PRODUCTS AND SERVICES IN SUPPORT OF HEMATOPOIETIC STEM CELL TRANSFERS
  • Table 15 COMMERCIAL OPPORTUNITIES FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION
    • CYTOKINES FOR STEM CELL THERAPY
  • Table 16 APPROVED BIOPHARMACEUTICALS FOR THE REGENERATION OF BLOOD AND IMMUNE CELLS AFTER CHEMOTHERAPY
    • G-CSF and GM-CSF
    • AMD3100
    • Erythropoietins
    • MARKET OPPORTUNITIES FOR REGENERATIVE CYTOKINES
  • Table 17 SALES OF THERAPEUTIC REGENERATIVE CYTOKINES FOR BLOOD AND IMMUNE DISEASES, THROUGH 2010 ($ MILLIONS)
  • Figure 2 SALES OF THERAPEUTIC REGENERATIVE CYTOKINES FOR BLOOD AND IMMUNE DISEASES, 2003-2010 ($ MILLIONS)
    • HARVESTING AND STORAGE OF UMBILICAL CORD BLOOD
  • Table 18 COMMERCIAL UMBILICAL CORD BLOOD STORAGE COMPANIES
    • Market Opportunities for Umbilical Cord Blood Storage
  • Table 19 FEES CHARGED BY MAJOR UMBILICAL CORD BLOOD BANKS, 2005 ($)
  • Table 20 WORLDWIDE REVENUES FROM CORD BLOOD HARVEST AND STORAGE, THROUGH 2010 ($ MILLIONS)
  • Figure 3 WORLDWIDE REVENUES FROM CORD BLOOD HARVEST AND STORAGE, 2003-2010 ($ MILLIONS)
    • EXPANSION OF STEM CELLS
      • Expansion of Stem Cells (Continued)
      • Market Opportunities for Stem Cell Expansion.
  • Table 21 WORLDWIDE REVENUES FROM EXPANSION AND CULTURE OF THERAPEUTIC STEM CELLS, THROUGH 2010 ($ MILLIONS)
  • Figure 4 WORLDWIDE REVENUES FROM EXPANSION AND CULTURE OF THERAPEUTIC STEM CELLS, 2003-2010 ($ MILLIONS)
    • GRAFT-VERSUS-HOST DISEASE
    • IMMUNE DEFICIENCIES
      • Acquired Immunodeficiency Syndrome
  • Table 22 AQUIRED IMMONDEFICIENCY CASES REPORTED BY YEAR IN THE U.S., 1985-2003
    • Natural Resistance
    • Current Therapies for AIDS
    • Progenitor Cell Therapies for AIDS
    • Market Opportunities for AIDS Therapies
  • Table 23 SIZE OF THE AIDS/HIV EPIDEMIC
    • SUMMARY: BLOOD AND IMMUNE DISEASES
  • Table 24 GLOBAL FORECAST OF REVENUES FOR BLOOD AND IMMUNE DISEASES ($ MILLIONS)
  • Table 5 GLOBAL FORECAST OF REVENUES FOR BLOOD AND IMMUNE DISEASES ($ MILLIONS)
    • SKIN
      • SKIN CELL PROGENITORS
      • BURNS
      • ULCERS
        • ULCERS (CONTINUED)
      • MARKET OPPORTUNITIES FOR SKIN CELL THERAPIES
        • MARKET OPPORTUNITIES FOR SKIN CELL THERAPIES (CONTINUED)
  • Table 25 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE WOUND THERAPY PRODUCTS, THROUGH 2010 ($ MILLIONS)
  • Figure 6 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE WOUND THERAPY PRODUCTS, 2003-2010 ($ MILLIONS)
    • BONE
      • BONE FRACTURES
        • Bone Metabolism
        • Current Therapies
        • Cell Therapies for Bone Fractures
        • Growth Factors and Morphogenic Proteins
  • Table 26 GROWTH FACTOR PRODUCTS FOR BONE HEALING
  • Table 27 GROWTH FACTORS DEVELOPED BUT NOT YET APPROVED FOR BONE INDICATIONS
    • Market Opportunities for Regenerative Therapies for Fractures and Spinal Fusions
  • Table 28 SPINAL FUSION DATA, U.S. 1998-2002 ($)
  • Table 29 NUMBER OF LOWER LEG FRACTURE, 1998-2002
  • Table 30 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE THERAPIES FOR SPINAL FUSIONS AND BONE FRACTURES ($ MILLIONS)
  • Figure 7 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE THERAPIES FOR SPINAL FUSIONS AND BONE FRACTURES ($ MILLIONS)
    • CARTILAGE
  • Table 31 PRODUCTS FOR REGENERATIVE CARTILAGE REPAIR
    • MENISCUS REPAIR
    • INJURIES OF THE KNEE
    • INTERVERTEBRAL DISC REGENERATION
    • MARKETS FOR CARTILAGE REPAIR
  • Table 32 GLOBAL FORECAST OF SALES OF CELL THERAPY PRODUCTS TO REPAIR CARTILAGE, THROUGH 2010 ($ MILLIONS)
  • Figure 8 GLOBAL FORECAST OF SALES OF CELL THERAPY PRODUCTS TO REPAIR CARTILAGE, 2003-2010 ($ MILLIONS)
    • CARDIOVASCULAR SYSTEM
      • CONGESTIVE HEART FAILURE
        • Current Therapies
      • CORONARY HEART DISEASE
        • Current Therapies
      • CELL THERAPIES FOR CHF OR CORONARY DISEASE
        • Cell Therapies for CHF or Coronary Disease (Continued)
        • Cell Therapies for CHF or Coronary Disease (Continued)
      • CARDIAC ARRYTHMIA
        • Current Therapy
        • Cell Therapies
      • MARKET OPPORTUNITIES FOR CARDIOVASCULAR CELL THERAPIES
  • Table 33 PREVALENCE OF HEART DISEASE IN U.S. ADULTS (18 YEARS AND OVER), 2002 (THOUSAND)
    • TEETH
    • HAIR
    • BRAIN AND NERVOUS SYSTEM
      • NEURAL STEM CELLS
      • LYSOSOMAL STORAGE DISEASES
      • DISORDERS OF THE MYELIN SHEATH
      • SPINAL CORD INJURY
        • Spinal Cord Injury (Continued)
      • STROKE
  • Table 34 DEATH RATES PER 100,000 FROM CEREBROVASCULAR DISEASE (STROKE) IN THE U.S., 1960 AND 2002
    • PARKINSONS DISEASE
      • Cell Therapies
        • Cell Therapies (Continued)
      • The Market Opportunities for Regenerative Treatments to Treat Neural Disease
    • EYES
      • EYES (CONTINUED)
        • Market Opportunities
    • LIVER
      • HUMAN CELL THERAPIES
        • Human Cell Therapies (Continued)
        • Markets for Regenerative Therapies for the Liver
    • KIDNEY
      • Potential Cell Therapies for Kidney Disease
      • Market Opportunities for Regenerative Kidney Therapies
    • DIABETES
  • Table 35 GLOBAL PREVALENCE OF DIABETES IN EUROPE, AGES 20 TO 79 2003 AND 2025 (THOUSANDS)
    • COMPLICATIONS OF DIABETES
      • Current Treatments
      • Edmonton Protocol
    • STEM CELL THERAPIES
      • Market Opportunities for Regenerative Diabetes Therapies
    • REPRODUCTIVE MEDICINE
      • MARKET OPPORTUNITIES FOR OOCYTE CRYOPRESERVATION
  • Table 36 GLOBAL FORECAST OF REVENUES DERIVED FROM OOCYTE STORAGE, THROUGH 2010 ($ MILLION)
  • Figure 9 GLOBAL FORECAST OF REVENUES DERIVED FROM OOCYTE STORAGE, 2003-2010 ($ MILLION)
• PRODUCTS USED IN CELL THERAPY AND REGENERATIVE MEDICINE
  • PRODUCTS USED FOR AMPLIFYING, CULTURING, OR TRANSFERRING STEM CELLS
    • AASTROMREPLICELL SYSTEM
    • MYOCATH PERCUTANEOUS DELIVERY SYSTEM
    • PLURIX BIOREACTOR SYSTEM
    • CYTOMATRIX
  • CYTOKINES AND GROWTH FACTORS
  • Table 37 CYTOKINES AND GROWTH FACTORS IN REGENERATIVE MEDICINE
    • AMD3100
    • ARANESP
    • BMP-7
    • CHRYSALIN
    • CTCE-0214
    • CYT 99 007
    • EPOGEN/PROCRIT
    • INFUSE/INDUCTOS
    • NEULASTA
    • NEUMEGA
    • NEUPOGEN
    • OP-1
    • REGRANEX GEL
    • THYMOSIN BETA FOUR
    • TUMOR GROWTH FACTOR ALPHA
    • LIVING CELL THERAPIES
      • HEMATOPOIETIC AND IMMUNE CELL THERAPIES
  • Table 38 LIVING BLOOD AND IMMUNE CELL THERAPEUTIC PRODUCTS IN DEVELOPMENT
    • Highly Purified Hematopoietic Stem Cells
    • HGTV-43
    • MP Cells
    • Procord
    • SKIN
  • Table 39 LIVING SKIN EQUIVALENTS USED THERAPEUTICALLY
    • Apligraf
    • Dermagraft
    • EpiCel
    • Hyalograft 3D
    • Laserskin Autograft
    • OrCel
    • CARTILAGE
  • Table 40 LIVING-CELL PRODUCTS USED THERAPEUTICALLY TO REPAIR CARTILAGE
    • Carticel
    • Cartilink
    • Chondrogen
    • Co.Don Chondrotransplant
    • Co.Don Chondrotransplant DISC
    • Hyalograft C
    • ICX-PRO
    • ICX-SKN
    • NEURAL STEM CELLS
      • HuCNS-SC
    • MUSCLE
  • Table 41 MUSCLE CELLS USED AS THERAPEUTIC PRODUCTS
    • Biopace
    • MyoCell
    • Myocell VT
    • Provacel
    • OTHER MESENCHYMAL CELLS
      • Prochymal
      • Tissue Repair Cells - Aastrom Bioscience
    • PANCREAS
      • IxSC-1
    • KIDNEY
      • Renal Assist Device
    • STEM CELL STORAGE
      • BIOARCHIVE STEM CELL SYSTEM
      • CCEL CELLULAR STORAGE FREEZER
• STRUCTURE OF THE INDUSTRY
  • CYTOKINE AND GROWTH FACTOR COMPANIES
  • Table 42 COMPANIES SUPPLYING APPROVED CYTOKINE OR GROWTH FACTOR THERAPIES
    • MARKET SHARES OF CYTOKINE AND GROWTH FACTOR COMPANIES
  • Table 43 RANKINGS AND MARKET SHARES OF COMPANIES FOR CYTOKINES AND GROWTH FACTORS IN 2004 (REVENUES)
    • PRODUCTS UNDER DEVELOPMENT
  • Table 44 COMPANIES DEVELOPING GROWTH FACTOR OR CYTOKINE PRODUCTS
    • UMBILICAL CORD STEM CELL COMPANIES
  • Table 45 2004 WORLDWIDE MARKET RANKINGS FOR UMBILICAL CORD STEM CELL STORAGE COMPANIES
    • CELL THERAPY COMPANIES
  • Table 46 FOCUS OF STEM AND PROGENITOR CELL THERAPY COMPANIES
  • Table 46 (CONTINUED)
  • Table 46 (CONTINUED)
    • PATENTS
      • PATENTS (CONTINUED)
  • Table 47 U.S. PATENT APPLICATIONS FROM JANUARY 1, 2001 THROUGH SEPTEMBER 8, 2005, WITH SELECTED STEM CELL SEARCH TERMS
  • Table 48 SELECTED U.S. STEM CELL PATENTS ISSUED BETWEEN JANUARY 2002 AND SEPTEMBER 2005
  • Table 48 (CONTINUED)
  • Table 48 (CONTINUED)
  • Table 48 (CONTINUED)
    • ATTRITION
  • Table 49 DISAPPEARING NAMES IN REGENERATIVE MEDICINE
• COMPANY PROFILES
  • AASTROM BIOSCIENCES
  • ADERANS RESEARCH INSTITUTE
  • ADVANCED CELL TECHNOLOGY
  • ADVANCED CELL THERAPEUTICS
  • AMGEN
  • ANORMED
  • ATHERSYS
  • BAXTER INTL.
  • BEFUTUR BIOTECHNOLOGIES
  • BIOHEART
  • BIOMATRIX SCIENTIFIC GROUP
  • BIOTISSUE, INC.
  • BIOTISSUE TECHNOLOGIES AG
  • BRAINSTORM CELL THERAPEUTICS
  • CELLARTIS
  • CELL BASED DELIVERY
  • CELLERANT THERAPEUTICS
  • CELLRESEARCH CORP.
  • CELLULAR DYNAMICS
  • CHEMOKINE THERAPEUTICS
  • CO.DON AG
  • CORCELL
  • CORD BLOOD AMERICA
  • CORD BLOOD REGISTRY
  • CYGENICS
    • CORDLIFE PTE, LTD./ CELL SCIENCES PTE, LTD.
  • CYTOMATRIX
  • CRYO-CELL INTL.
  • CYTHERA
  • CYTORI THERAPEUTICS
  • DENTIGENIX, INC.
  • ENCELLE
  • ENZO BIOCHEM
  • EXTENDFERTILITY
  • FIDIA FARMACEUTICI SPA
  • FREZER, INC.
  • GENZYME BIOSURGERY
  • GENVEC
  • GERON
  • HISTOSTEM
  • INTERCYTEX
  • INTERFACE BIOTECH A/S
  • ISLET TECHNOLOGY
  • ISTO TECHNOLOGIES
  • IXION BIOTECHNOLOGY
  • KALEIDOS PHARMACEUTICAL
  • JOHNSON & JOHNSON
  • LIFEBANK CRYOGENICS
  • MEDRA
  • MESOBLAST, LTD.
  • MILTENYI BIOTEC GMBH
  • MORPHOGENESIS
  • NEOSTEM
  • NEPHROS THERAPEUTICS
  • NEURALSTEM BIOPHARMACEUTICALS
  • NEURONYX
  • NOVARTIS INTERNATIONAL AG
  • NS GENE A/S
  • ODONTIS
  • ORGANOGENESIS
  • ORTEC INTL.
  • ORTHOLOGIC
  • OSIRIS THERAPEUTICS
  • PHARMA FRONTIERS
  • PHARMASTEM THERAPEUTICS
  • PLURISTEM LIFE SYSTEMS
  • PRIMEGEN BIOTECH, LLC
  • PROGENITOR CELL THERAPY
  • PRONEURON BIOTECHNOLOGIES
  • REGENERX BIOPHARMACEUTICALS
  • RENEURON
  • SANERON CCEL THERAPEUTICS, INC.
  • STEMCELLS, INC.
  • STEMCELL PHARMA, INC.
  • STEM CELL SCIENCES
  • STEM CELL THERAPEUTICS CORP.
  • STEM CELL THERAPY INTL.
  • THERMOGENESIS
  • TISSERA
  • U.S. BIODEFENSE, INC.
  • VESTA THERAPEUTICS
  • VIACELL
  • WICELL RESEARCH INSTITUTE
• APPENDIX
  • GLOSSARY OF TERMS AND ABBREVIATIONS
    • GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED)
    • GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED)
    • GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED)
    • GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED)
    • GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED)
    • GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED)
    • GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED)
    • GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED)
• LIST OF TABLES
• Summary Table:
• Table 1 PERCENT OF PERSONS USING PRESCRIPTION DRUGS IN THE PAST MONTH IN THE U.S., 1999-2000
• Table 2 SELECTED CYTOKINES OR GROWTH FACTORS RELEVANT TO REGENERATIVE MEDICINE
• Table 3 LEADING CAUSES OF DEATH IN THE U.S., 2001
• Table 4 PREVALENCE OF MEDICAL CONDITIONS IN THE U.S. WITH POTENTIAL CELL THERAPIES
• Table 5 AGING OF THE U.S. POPULATION
• Table 6 POPULATION OF COUNTRIES OF THE EUROPEAN UNION, 2003
• Table 7 DESCENDANTS OF THE HUMAN MESENCHYMAL STEM CELL
• Table 8 A PARTIAL LIST OF DISEASES TREATED USING
• CORD BLOOD STEM CELLS
• Table 9 DERIVATION OF BODY TISSUE TYPES FROM GERM LAYERS
• Table 10 CELL TYPES DERIVED FROM EMBRYONIC STEM CELLS IN VITRO
• Table 11 MARKERS OF PLURIPOTENT CELLS IN MOUSE, MAN, AND MONKEY
• Table 12 EMBRYONIC STEM CELL LINES THAT MEET NIH FUNDING REQUIREMENTS, WHICH ARE AVAILABLE FOR SHIPPING
• Table 13 FOOD AND DRUG ADMINISTRATION BODIES INVOLVED IN IMPLANT REGULATION
• Table 14 A PARTIAL LIST OF DISEASES TREATED WITH HEMATOPOIETIC STEM CELLS
• Table 15 COMMERCIAL OPPORTUNITIES FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION
• Table 16 APPROVED BIOPHARMACEUTICALS FOR THE REGENERATION OF BLOOD AND IMMUNE CELLS AFTER CHEMOTHERAPY
• Table 17 SALES OF THERAPEUTIC REGENERATIVE CYTOKINES FOR BLOOD AND IMMUNE DISEASES, THROUGH 2010 ($ MILLIONS)
• Table 18 COMMERCIAL UMBILICAL CORD BLOOD STORAGE COMPANIES
• Table 19 FEES CHARGED BY MAJOR UMBILICAL CORD BLOOD BANKS, 2005 ($)
• Table 20 WORLDWIDE REVENUES FROM CORD BLOOD HARVEST AND STORAGE, THROUGH 2010 ($ MILLIONS)
• Table 21 WORLDWIDE REVENUES FROM EXPANSION AND CULTURE OF THERAPEUTIC STEM CELLS, THROUGH 2010 ($ MILLIONS)
• Table 22 AQUIRED IMMONDEFICIENCY CASES REPORTED BY YEAR IN THE U.S., 1985-2003
• Table 23 SIZE OF THE AIDS/HIV EPIDEMIC
• Table 24 GLOBAL FORECAST OF REVENUES FOR BLOOD AND IMMUNE DISEASES ($ MILLIONS)
• Table 25 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE WOUND THERAPY PRODUCTS, THROUGH 2010 ($ MILLIONS)
• Table 26 GROWTH FACTOR PRODUCTS FOR BONE HEALING
• Table 27 GROWTH FACTORS DEVELOPED BUT NOT YET APPROVED FOR BONE INDICATIONS
• Table 28 SPINAL FUSION DATA, U.S. 1998-2002 ($)
• Table 29 NUMBER OF LOWER LEG FRACTURE, 1998-2002
• Table 30 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE THERAPIES FOR SPINAL FUSIONS AND BONE FRACTURES ($ MILLIONS)
• Table 31 PRODUCTS FOR REGENERATIVE CARTILAGE REPAIR
• Table 32 GLOBAL FORECAST OF SALES OF CELL THERAPY PRODUCTS TO REPAIR CARTILAGE, THROUGH 2010 ($ MILLIONS)
• Table 33 PREVALENCE OF HEART DISEASE IN U.S. ADULTS (18 YEARS AND OVER), 2002 (THOUSAND)
• Table 34 DEATH RATES PER 100,000 FROM CEREBROVASCULAR DISEASE (STROKE) IN THE U.S., 1960 AND 2002
• Table 35 GLOBAL PREVALENCE OF DIABETES IN EUROPE, AGES 20 TO 79, 2003 AND 2005 (THOUSANDS)
• Table 36 GLOBAL FORECAST OF REVENUES DERIVED FROM OOCYTE STORAGE, THROUGH 2010 ($ MILLION)
• Table 37 CYTOKINES AND GROWTH FACTORS IN REGENERATIVE MEDICINE
• Table 38 LIVING BLOOD AND IMMUNE CELL THERAPEUTIC PRODUCTS IN DEVELOPMENT
• Table 39 LIVING SKIN EQUIVALENTS USED THERAPEUTICALLY
• Table 40 LIVING-CELL PRODUCTS USED THERAPEUTICALLY TO REPAIR CARTILAGE
• Table 41 MUSCLE CELLS USED AS THERAPEUTIC PRODUCTS
• Table 42 COMPANIES SUPPLYING APPROVED CYTOKINE OR GROWTH FACTOR THERAPIES
• Table 43 RANKINGS AND MARKET SHARES OF COMPANIES FOR CYTOKINES AND GROWTH FACTORS IN 2004 (REVENUES)
• Table 44 COMPANIES DEVELOPING GROWTH FACTOR OR CYTOKINE PRODUCTS
• Table 45 2004 WORLDWIDE MARKET RANKINGS FOR UMBILICAL CORD STEM CELL STORAGE COMPANIES
• Table 46 FOCUS OF STEM AND PROGENITOR CELL THERAPY COMPANIES
• Table 47 U.S. PATENT APPLICATIONS FROM JANUARY 1, 2001 THROUGH SEPTEMBER 8, 2005, WITH SELECTED STEM CELL SEARCH TERMS
• Table 48 SELECTED U.S. STEM CELL PATENTS ISSUED BETWEEN JANUARY 2002 AND SEPTEMBER 2005
• Table 49 DISAPPEARING NAMES IN REGENERATIVE MEDICINE
• LIST OF FIGURES
• Summary Figure:
• Figure 1 HEMATOPOIESIS
• Figure 2 SALES OF THERAPEUTIC REGENERATIVE CYTOKINES FOR BLOOD AND IMMUNE DISEASES, 2003-2010 ($ MILLIONS)
• Figure 3 WORLDWIDE REVENUES FROM CORD BLOOD HARVEST AND STORAGE, 2003-2010 ($ MILLIONS)
• Figure 4 WORLDWIDE REVENUES FROM EXPANSION AND CULTURE OF THERAPEUTIC STEM CELLS, 2003-2010 ($ MILLIONS)
• Table 5 GLOBAL FORECAST OF REVENUES FOR BLOOD AND IMMUNE DISEASES ($ MILLIONS)
• Figure 6 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE WOUND THERAPY PRODUCTS, 2003-2010 ($ MILLIONS)
• Figure 7 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE THERAPIES FOR SPINAL FUSIONS AND BONE FRACTURES ($ MILLIONS)
• Figure 8 GLOBAL FORECAST OF SALES OF CELL THERAPY PRODUCTS TO REPAIR CARTILAGE, 2003-2010 ($ MILLIONS)
• Figure 9 GLOBAL FORECAST OF REVENUES DERIVED FROM OOCYTE STORAGE, 2003-2010 ($ MILLION)